Patents Examined by Kimberly Ballard
  • Method for preparing PHFS-like Tau aggregates
    Patent number: 11629175
    Abstract: The invention relates to a method for preparing PHFs-like Tau aggregates and to a method for identifying compounds that are inhibitors of Tau protein aggregation, blockers of Tau seeding and propagation, and imaging agents that specifically bind PHF.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: April 18, 2023
    Assignee: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
    Inventors: Hilal A. Lashuel, Nadine Ait-Bouziad
  • Heterologous administration of tau vaccines
    Patent number: 11591377
    Abstract: Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described. The methods include administering a liposomal priming composition containing tau peptides, preferably phosphorylated tau peptides, and a conjugate boosting composition containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: February 28, 2023
    Assignees: Janssen Pharmaceuticals, Inc., AC Immune SA
    Inventors: Elizabeth Anne Ramsburg, Donata De Marco, Chakkumkal Anish, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, David Hickman, Nicolas Piot, Saroj Raj Ghimire
  • Anti-Tau antibodies and uses thereof
    Patent number: 11578120
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: February 14, 2023
    Assignees: Eisai R&D Management Co., Ltd., UCL Business LTD
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Ameliorating nervous systems disorders
    Patent number: 11564949
    Abstract: The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: January 31, 2023
    Assignee: The Regents of the University of California
    Inventors: Arnold Kriegstein, John L. R. Rubenstein, Scott C. Baraban, Arturo Alvarez-Buylla
  • Polypeptide-antibody complexes and uses thereof
    Patent number: 11531030
    Abstract: Complexes containing a labeled polypeptide and an antibody, and the use of such complexes as research, diagnostic, and clinical tools, are described herein.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: December 20, 2022
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Wendy K. Nevala, Svetomir N. Markovic, John T. Butterfield, Daniel J. Knauer
  • Method of treating osteoarthritis with an antibody to NGF
    Patent number: 11518804
    Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: December 6, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
  • Methods and compositions for increasing alpha-L-iduronidase activity in the CNS
    Patent number: 11512145
    Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in ?-L-Iduronidase in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an ?-L-Iduronidase. A therapeutically effective systemic dose is based on the specific CNS uptake characteristics of human insulin receptor antibody-?-L-Iduronidase fusion antibodies as described herein.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 29, 2022
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Detection of CD-155, the poliovirus receptor
    Patent number: 11506666
    Abstract: A reliable assay to specifically detect CD155 in tissue sections has widespread use because CD155 is expressed widely among tumor types. Additionally, detected expression of CD 155 in glioblastoma cells is at levels commensurate with susceptibility to PVSRIPO (a poliovirus construct) infection and killing. An anti-CD155 antibody can achieve mono-specific detection of CD155 in immunoblots of tumor homogenates and immunohistochemistry of tumor formalin fixed, paraffin embedded sections. The assay can be used to determine appropriate use of PVSRIPO in oncolytic immunotherapy against cancers.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: November 22, 2022
    Assignee: Duke University
    Inventors: Darell D. Bigner, Vidyalakshmi Chandramohan, Matthias Gromeier
  • Tau immunotherapy
    Patent number: 11492393
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: November 8, 2022
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
    Patent number: 11478556
    Abstract: In alternative embodiments, provided are methods for increasing levels of and/or upregulating the expression of ApoA-I Binding Protein (APOA1BP, AIBP, or AI-BP) to treat, ameliorate, prevent, reverse, decrease the severity or duration of: a neuropathic pain, including an inflammation-induced neuropathic pain, a nerve or CNS inflammation, a, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) (e.g., cisplatin-induced allodynia) a neurodegeneration or neurodegenerative disease or condition, a migraine, and/or a hyperalgesia.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: October 25, 2022
    Assignee: The Regents of the University of California
    Inventors: Yury Miller, Tony L. Yaksh
  • Polypeptide and antibody bound to polypeptide
    Patent number: 11479603
    Abstract: An antibody for being specifically bound to a pro brain-derived neurotrophic factor (pro-BDNF) and a bound epitope. The antibody and the protein are used for treating autoimmune diseases. By inhibiting the activity induced by the pro-BDNF, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, lupus nephriti, chronic obstructive pulmonary diseases, asthma or cystic fibrosis, multiple sclerosis and other autoimmune diseases are treated.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: October 25, 2022
    Assignee: SHANGHAI YILE BIOTECHNOLOGY CO., LTD.
    Inventors: Xiumei Cai, Ruping Dai, Huamao Wang
  • Methods for treating or preventing migraine headache
    Patent number: 11466090
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: October 11, 2022
    Assignee: AMGEN INC.
    Inventors: Hong Sun, Eduardo Dunayevich, Robert A. Lenz, Gabriel Vargas
  • Immunotherapeutic compositions for the treatment of Alzheimer's disease
    Patent number: 11419924
    Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes A?1-42 or an beta amyloid self epitope (e.g. A?1-15, or other 7-mer or 15-mer peptide epitopes derived from A?1-42) conjugated to an immunogenic carrier formulated in a water-in-oil Th2-biased adjuvant/delivery system.
    Type: Grant
    Filed: September 6, 2021
    Date of Patent: August 23, 2022
    Assignee: MERCIA PHARMA, INC.
    Inventors: Peter Blackburn, Stephen Grimes
  • Neuronal survival and axonal regeneration through increasing mitochondrial motility
    Patent number: 11413325
    Abstract: Disclosed are compositions and methods for promoting survival of or axon regeneration in neurons by increasing mitochondrial motility in the neuron. Also disclosed are methods to treat neuronal injury and disease and disorders characterized by neuronal injury. Agents that increase Armcx1 activity, such as Armcx1 polypeptide or vectors comprising nucleic acid encoding Armcx1 polypeptide, are proposed for use in the methods. Pharmaceutical composition comprising the agents, and methods for identifying additional agents are also disclosed.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 16, 2022
    Assignee: THE CHILDREN'S MEDICAL CENTER
    Inventors: Zhigang He, Thomas L. Schwarz, Cartoni Romain
  • Prognostic biomarker in cancer
    Patent number: 11407827
    Abstract: The present invention is directed to a monoclonal antibody or an antigen-binding portion thereof having specific binding affinity to RING finger protein 4 (RNF4). The invention is further directed to use of the antibody or an antigen-binding portion thereof in detecting a RNF4-associated disease in a subject, such as cancer.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 9, 2022
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Amir Oryan (Orian), Yaniv Zohar, Emily Hersh-Avitan
  • Erenumab compositions and uses thereof
    Patent number: 11407838
    Abstract: The present invention relates to compositions comprising erenumab and one or more erenumab variants, including isomerization variants, deamidation variants, acidic variants, and HMW species. Pharmaceutical formulations comprising the erenumab compositions and methods of using and characterizing the compositions are also described.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: August 9, 2022
    Assignee: AMGEN INC.
    Inventors: Kenneth Lawson, Noel Rieder, Suminda Hapuarachchi, Jose Gregorio Ramirez
  • EGFR targeted therapy of neurological disorders and pain
    Patent number: 11396548
    Abstract: The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to the epidermal growth factor receptor (EGFR) as a clinical target for treatment of neurological disorders, preferably in conjunction with neuropathic pain. The invention relates in more detail to compositions comprising inhibitors of EGFR.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: July 26, 2022
    Assignee: Sykehuset Sørlandet HF
    Inventors: Christian Kersten, Marte Grønlie Cameron, Svein Mjåland
  • Methods for treatment of social dysfunction neurological disorders and seizures
    Patent number: 11389509
    Abstract: The present disclosure relates to methods of treating social dysfunction neurological disorders in an animal subject, comprising administering to the subject a therapeutically effective amount of a compound that increases STAT1 activity, and to a method of treating seizures in an animal subject, comprising administering to the subject a therapeutically effective amount of a compound that increases STAT1 activity. In some embodiments, the compound is IFN-?.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: July 19, 2022
    Assignee: University of Virginia Patent Foundation
    Inventors: Anthony J. Filiano, Jonathan Kipnis
  • Anti-Siglec-7 antibodies and methods of use thereof
    Patent number: 11390680
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: July 19, 2022
    Assignee: Alector LLC
    Inventors: Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
  • Methods and compositions for treatment of amyloid deposition diseases
    Patent number: 11382974
    Abstract: Methods and pharmaceutical compositions for treatment of amyloid deposition diseases using chimeric (e.g., mouse-human) antibody are disclosed, including a method for treating amyloid deposition diseases with cardiac involvement by administering pharmaceutical compositions comprising a chimeric anti-amyloid fibril antibody. The methods herein can improve myocardial function in patients diagnosed with light chain amyloid light chain amyloidosis (ALA) having a cardiac involvement in as little as three weeks after treatment.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: July 12, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventor: Suzanne Lentzsch